FilingReader Intelligence
Lukang Pharmaceutical receives gefitinib drug approval, profit margin rises
July 14, 2025 at 12:00 PM UTC•By FilingReader AI
Shandong Lukang Pharmaceutical received approval for gefitinib tablet and its API, enhancing its product portfolio.
The company's sales net profit margin grew to 6.55% in 2024, driven by improved product mix and asset disposal gains.
Lukang continues strategic investments in new drug R&D, advanced manufacturing, and biological pesticides across broad therapeutic areas.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Supplementary Source Documents
Reply to the inquiry letter on the review of the application documents for the issuance of shares to specific objects by Shandong Lukang Pharmaceutical Co., Ltd. (revised version)July 7, 2025 at 08:00 AM UTC
Announcement of Lukang Pharmaceutical on Obtaining Drug Registration Certificate and Approval Notice of Chemical API Marketing ApplicationJuly 8, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Shandong Lukang Pharmaceutical publishes news
Free account required • Unsubscribe anytime